Johnson & Johnson Stock Forecast for 2022 - 2025 - 2030
Updated on 10/01/2022
Johnson & Johnson Stock Forecast and Price Target
Johnson & Johnson's most recent price target of $182.00 for 2022 was provided by three renowned analysts over the past few months, with an average prediction of $182.00. If this prediction is correct, Johnson & Johnson's stock could rise by 10.62 percent from its current trading price. The potential increase for the stock is $182.00 per share, with a possible range of $164.00 to $215.00. Even if you are not interested in JNJ stock, you should still be aware of its competitors.
10.62% Upside
Johnson & Johnson Fair Value Forecast for 2022 - 2025 - 2030
Johnson & Johnson's Price has grown in the last four years, jumping from $128.63 to $172.68 – an increase of 34.25%. In the next year, analysts predict that Fair Value will reach $180.78 – an increase of 4.69%. For the next nine years, the forecast is for Fair Value to grow by 32.65%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$142.72 | Buy/Sell | $164.23 | 9.30% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
14
|
$98.29 | Buy/Sell | $128.88 | 27.68% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
18
|
£99.33 | Buy/Sell | £136.08 | 41.24% |
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
2
|
$71.71 | Buy/Sell | $79.05 | 15.74% |
| AMGN Stock Forecast | Amgen | Hold |
9
|
$228.41 | Buy/Sell | $246.51 | 11.64% |
Johnson & Johnson Revenue Forecast for 2022 - 2025 - 2030
Johnson & Johnson's Revenue has grown in the last four years, jumping from $76.45B to $93.78B – an increase of 22.66%. In the next year, analysts predict that Revenue will reach $96.30B – an increase of 2.69%. For the next nine years, the forecast is for Revenue to grow by 12.28%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$226.12 | Buy/Sell | $278.08 | 23.83% |
| MMM Stock Forecast | 3M | Hold |
16
|
$112.30 | Buy/Sell | $147.79 | 21.99% |
| BSX Stock Forecast | Boston Scientific | Buy |
15
|
$39.34 | Buy/Sell | $49.85 | 22.01% |
.jpg)
Johnson & Johnson Dividend per Share Forecast for 2022 - 2025 - 2030
In the last four years, Johnson & Johnson's Dividend per Share has increased by 26.20%, going from $3.32 to $4.19. In the next year, analysts are expecting an increase in Dividend per Share, predicting it will reach $4.45 – an increase of 6.21%. The Johnson & Johnson forecast is for Dividend per Share to reach $5.75 or grow by 37.23%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Outperform |
7
|
47.72€ | Buy/Sell | 67.79€ | 66.60% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
18
|
¥3.63k | Buy/Sell | ¥0.00 | 23.97% |
| BIIB Stock Forecast | Biogen | Outperform |
11
|
$264.28 | Buy/Sell | $242.78 | 2.16% |
Johnson & Johnson Free Cash Flow Forecast for 2022 - 2025 - 2030
Johnson & Johnson's Free Cash Flow has increased by 11.14% In the last four years, going from $17.78B to $19.76B. In the next year, analysts expect Free Cash Flow to reach $23.17B – an increase of 17.29%. For the next nine years, the forecast is for Free Cash Flow to grow by 47.66%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAS Stock Forecast | BASF | Outperform |
11
|
38.85€ | Buy/Sell | 78.27€ | 41.57% |
| BNTX Stock Forecast | BioNTech | Outperform |
12
|
$133.60 | Buy/Sell | $0.00 | 50.00% |
| BAX Stock Forecast | Baxter International | Outperform |
17
|
$55.30 | Buy/Sell | $69.92 | 24.77% |
Johnson & Johnson Net Income Forecast for 2022 - 2025 - 2030
In the last four years, Johnson & Johnson's Net Income has grown, increasing from $1.30B to $20.88B – an increase of 1506.00%. For next year, the 17 analysts predict Net Income of $27.22B, which would mean an increase of 30.39%. Over the next nine years, the pros' prediction is Net Incomeof $29.27B, which would mean a nine-year growth forecast of 40.20%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALC Stock Forecast | Alcon | Outperform |
15
|
CHF55.44 | Buy/Sell | CHF0.00 | 52.71% |
| BEI Stock Forecast | Beiersdorf | Outperform |
17
|
100.20€ | Buy/Sell | 102.71€ | 11.78% |
| CHD Stock Forecast | Church & Dwight | Hold |
11
|
$72.92 | Buy/Sell | $90.41 | 22.19% |
Johnson & Johnson EBITDA Forecast for 2022 - 2025 - 2030
In the last four years, Johnson & Johnson's EBITDA has grown, increasing from $24.54B to $32.64B – a growth of 33.00%. The next year looks promising for Johnson & Johnson, with analysts predicting EBITDA of $34.27B – an increase of 5.02%. Over the next nine years, experts anticipate that Johnson & Johnson's EBITDA will grow at a rate of 66.01%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BGNE Stock Forecast | BeiGene | Outperform |
6
|
$136.28 | Buy/Sell | $0.00 | 120.14% |
| AKZA Stock Forecast | Akzo Nobel N.V. | Outperform |
18
|
56.80€ | Buy/Sell | 113.10€ | 91.02% |
| AFX Stock Forecast | Carl Zeiss Meditec | Outperform |
18
|
103.15€ | Buy/Sell | 165.40€ | 44.45% |
Johnson & Johnson EBIT Forecast for 2022 - 2025 - 2030
In the last four years, Johnson & Johnson's EBIT has grown by 33.60%, from $18.90B to $25.25B. For the next year, analysts are expecting EBIT to reach $30.91B – an increase of 22.45%. Over the next nine years, experts predict that EBIT will grow by 39.26%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BBWI Stock Forecast | Bath & Body Works | Outperform |
15
|
$33.63 | Buy/Sell | $52.00 | 42.73% |
| CLN Stock Forecast | Clariant | Hold |
18
|
CHF14.85 | Buy/Sell | CHF19.93 | 31.99% |
| 7747 Stock Forecast | Asahi Intecc | Outperform |
16
|
¥2.33k | Buy/Sell | ¥0.00 | 29.03% |
Johnson & Johnson EPS Price Prediction Forecast for 2022 - 2025 - 2030
Johnson & Johnson's EPS has grown in the last four years, jumping from $7.30 to $9.80 – an increase of 34.25%. In the next year, analysts predict that EPS will reach $10.26 – an increase of 4.69%. For the next nine years, the forecast is for EPS to grow by 32.65%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CCXI Stock Forecast | ChemoCentryx | Outperform |
8
|
$51.66 | Buy/Sell | $34.75 | 24.85% |
| ALKS Stock Forecast | Alkermes | Hold |
10
|
$22.46 | Buy/Sell | $0.00 | 42.48% |
| AUROPHARMA Stock Forecast | Aurobindo Pharma | Outperform |
18
|
Rp509.70 | Buy/Sell | Rp946.91 | 56.96% |
Site Navigation
.jpg)